Listar INIBIC-VC - Artigos por título
Mostrando ítems 4-23 de 37
-
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
(Wiley, 2017-07-16)[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ... -
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
(Taylor & Francis, 2019-01-03)[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in ... -
DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: a retrospective study
(Springer, 2019-10-23)[Abstract] Background. Most of the circulating Vitamin D (VitD) is transported bound to vitamin D-binding protein (DBP), and several DBP single nucleotide polymorphisms (SNPs) have been related to circulating VitD concentration ... -
Deep-Sequencing Reveals Broad Subtype-Specific HCV Resistance Mutations Associated with Treatment Failure
(Elsevier, 2019-12-16)[Abstract] A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ... -
Despistaje de la infección por el virus de inmunodeficiencia humana en Atención Primaria mediante indicadores de sospecha: estudio DIVAPIS
(Sociedade Galega de Medicina Interna (SOGAMI), 2019-10)[Resumen] Introducción: El diagnóstico precoz de la infección por VIH es fundamental para mejorar el pronóstico de la enfermedad y evitar nuevos contagios. Atención Primaria (AP), al ser el primer nivel asistencial al que ... -
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
(BMJ, 2020-10-13)[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ... -
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
(Frontiers, 2019-08-03)[Abstract] In Western Europe, the HIV-1 epidemic among men who have sex with men (MSM) is dominated by subtype B. However, recently, other genetic forms have been reported to circulate in this population, as evidenced ... -
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
(Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Effectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practice
(Willey Online Library, 2020-03-17)[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ... -
Effectiveness and Safety of Sofosbuvir/Velpatasvir ± Ribavirin vs Glecaprevir/Pibrentasvir in Genotype 3 Hepatitis C Virus Infected Patients
(BMJ Publishing Group, 2020-02-07)[Abstract] Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ... -
Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era
(Elsevier, 2020-06-08)[Abstract] Purpose: To describe the epidemiology of critical disease in HIV-infected patients during the current highly active antiretroviral therapy (HAART) era and to identify hospital mortality predictors. Methods: ... -
Hepatitis E 3ra genotype infection in people living with HIV in Spain
(Frontiers, 2020-09-11)[Abstract] Background: The objective of our study was to assess the prevalence and incidence of HEV in people living with HIV (PLWH) in a Spanish national cohort. Methods: Retrospective longitudinal study including PLWH ... -
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4
(Wiley, 2017-05-08)[Abstract] Background and Aims. Hepatitis C (HCV) therapy with Sofosbuvir (SOF)/Simeprevir (SMV) in clinical trials and real‐world clinical practice, showed high rates of sustained virological response (SVR) in non‐cirrhotic ... -
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
(Springer, 2015-07-09)[Abstract] It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, ... -
Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus
(BMJ, 2019-06-13)[Abstract] Objectives Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety. The objective ... -
Late HIV diagnosis but earlier antiretroviral treatment initiation in northwest Spain: impact of current treatment guidelines
(Sage, 2019-01-10)[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ... -
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis
(Wiley, 2015-06-30)[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods. A ... -
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
(Plos ONE, 2019-06-03)[Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ... -
Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV
(Wiley, 2017-02-23)[Abstract] Objectives. The aim of this study was to compare liver-related mortality and liver-related hospitalizations for persons living with HIV (PLWH) with and without hepatitis C virus (HCV) exposure, and to estimate ... -
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
(Wiley, 2016-06-06)[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ...